Introduction {#s1}
============

Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in the western world. CLL is characterized by the clonal expansion and accumulation of malignant B-cells in the blood stream and homing tissues (such as bone marrow and lymphoid organs). In the CLL context, positive status of ZAP70, unmutated IgVH, as well as the presence of the chromosomal aberrations *del17p* and *del11q*---spanning TP53 and ATM locus, respectively---are considered as poor outcome predictors ([@B1]--[@B3]).

One important target for CLL treatment is B-cell receptor (BCR) signaling, since it is involved in B-cell proliferation, differentiation, and migration ([@B4], [@B5]). In CLL, both ligand independent and antigen-induced BCR activation are present, supported by constitutive phosphorylation of BCR signaling components ([@B6], [@B7]). Ibrutinib targets BCR signaling through the irreversible inhibition of the Bruton\'s tyrosine kinase (BTK) ([@B8]). Ibrutinib is among the leading agents used in CLL treatment; however, resistant cases have already arisen, and discontinuation of treatment often triggers disease progression ([@B9], [@B10]). Most relapses to ibrutinib treatment occur due to acquired mutations in BTK or its target PLCγ2, perhaps facilitating the success with alternative targeted therapies ([@B11]). In contrast the mechanisms of *DeNovo* resistance to ibrutinib are not well defined.

Therefore, there is a need for additional therapeutic approaches to target CLL.

Aberrant metabolism with respect to normal cells is a hallmark of cancer. Changes in glucose use by cancer cells was the first metabolic alteration described by Warburg, who proposed enhanced use of aerobic glycolysis in cancer cells. Also, altered glutamine use has been reported in cancer ([@B12]). More recently atypical use of fatty acids has been described in several types of cancers including glioblastoma, breast cancer, and CLL ([@B13]--[@B17]). Recently, the characterization of metabolic reprogramming has led to novel therapeutic strategies against a variety of cancers ([@B18]). The inhibition of glucose uptake and mitochondrial respiration, using ritonavir and metformin respectively, has been approved for the treatment of Multiple myeloma ([@B19]). As well, CB-839---a glutaminase inhibitor---is in clinical trials for AML and ALL treatment (clinicaltrials.gov). In CLL, the use of metformin alone or in combination with ritonavir is being tested at clinical trials (clinicaltrials.gov) ([@B20]).

Normal and cancer cells can use glucose and other metabolites, such as fatty acids or amino acids (i.e., glutamine), to obtain energy and building blocks to fulfill their metabolic needs. Thus, metabolite availability has an impact on intracellular processes. In line with this, we have observed differential metabolic responses when cells are exposed to high or limited glucose levels ([@B21]). As well, extracellular cystine can modulate intracellular glutamate dependency---through the activation of the glutamate-cystine antiporter: xCT ([@B22]). Furthermore, metabolites participate in the regulation of intracellular signaling cascades and redox state amongst others. Alternative metabolic reprogramming has been observed in cancer cell lines exposed to physiological concentrations of metabolites in the media ([@B23]).

Although some general assumptions have been reached for cancer cell metabolism; the metabolite utilization in the cell can be quite different depending on the cancel cell type. For instance, transaminases and glutamate dehydrogenase compete to perform glutamate catabolism in breast tumors, depending on the quiescent or proliferative state of the cells ([@B24]).

Our knowledge of CLL cell metabolism is still partial, limiting the design of metabolic approaches toward this disease. CLL lymphocytes have an operative glycolytic pathway ([@B21]), but they do not follow the Warburg effect. Instead, some reports suggest the preferential use of fatty acid metabolism in these cells ([@B25]). In contrast, the increase in glucose metabolism and the use of amino acids on anaplerotic reactions of the TCA cycle has also been proposed ([@B26]). The overexpression of oxoglutarate dehydrogenase (OGDC) and isocitrate dehydrogenase (IDH), two enzymes that facilitate the use of the TCA cycle in the forward and reverse directions (i.e., oxidation or reduction of α-ketoglutarate, respectively) ([@B27]), support the idea of metabolic plasticity in CLL. In addition, mitochondrial number, mass, activity, and ROS production are increased in CLL compared to normal B-cell lymphocytes ([@B28]). Regarding fatty acid metabolism, the production of citrate for fatty acid synthesis is favored via isocitrate dehydrogenase and mitochondrial transhydrogenase (NNT), overexpressed by primary CLL lymphocytes. Interestingly, CLL lymphocytes overexpress enzymes associated with enhanced fatty acid oxidation (FAO) as well ([@B26], [@B29])

Apart from their known role in DNA damage response and cell cycle control, ATM and TP53 are regulators of central carbon metabolism and redox homeostasis ([@B30]--[@B33]). Therefore, it is possible that del11q and del17p promote specific metabolic alterations in CLL cells. In line with this, exacerbated mitochondrial respiration in del17p CLL cells has been documented ([@B34]). Moreover, we recently reported that glutamine metabolism is altered in del11q positive compared to del11q negative CLL cells. As a result, del11q positive CLL lymphocytes display an increased sensitivity to glutaminase inhibition ([@B35]). Metabolic alterations due to cryopreservation have been reported in primary non-malignant human cells isolated from peripheral blood ([@B36]--[@B38]). In spite of possible limitation, we used cryopreserved primary CLL available in our bank to undertake the task of shedding light into the role of BTK on intrinsic metabolic rewiring in primary CLL lymphocytes and to seek for metabolic traits that can be exploited to reduce *DeNovo* ibrutinib resistance. Noteworthy, available metabolic studies in CLL were carried out using cryopreserved CLL lymphocytes.

Materials and methods {#s2}
=====================

Patient samples
---------------

Peripheral blood samples donated from 30 patients with a diagnosis of B-CLL attending the Jewish General Hospital Hematology Clinic were utilized in this study. CLL lymphocytes were isolated by Ficoll-Hypaque as previously described ([@B39]). This study was carried out in accordance with the recommendations of the published guidelines of the TCPS2---Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (2014), Jewish General Hospital Research Ethics Committee. The protocol was approved by the Jewish General Hospital Research Ethics Committee. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The characteristics of these samples are summarized on Table [1](#T1){ref-type="table"}.

###### 

Patient sample characteristics: ibrutinib sensitivity, IgVH mutation status, diabetic status, Clinical Status, RAI stage, del13q14 status, and del17p status.

  **Patient \#**   **Ibrutinib sensitivity**   **IgVH status**   **Diabetic status**   **Clinical status**   **RAI stage**   **Del13q status**   **Del17p status**
  ---------------- --------------------------- ----------------- --------------------- --------------------- --------------- ------------------- -------------------
  1                Sen                         M                 N                     T                     III             \+                  --
  2                Sen                         M                 N                     NA                    IV              NA                  --
  3                Sen                         M                 D                     T                     O               \+                  --
  4                Sen                         M                 H                     T                     IV              \+                  --
  5                Sen                         M                 NA                    T                     NA              NA                  --
  6                Sen                         U                 N                     NT                    I               \+                  --
  7                Sen                         U                 N                     NT                    II              \+                  --
  8                Sen                         U                 N                     NT                    II              --                  --
  9                Sen                         U                 D                     NA                    NA              \+                  --
  10               Sen                         U                 NA                    NT                    II              \+                  --
  11               Sen                         U                 NA                    NT                    NA              --                  --
  12               Res                         M                 N                     T                     II              --                  --
  13               Res                         M                 N                     T                     II              \+                  --
  14               Res                         M                 N                     T                     III             --                  --
  15               Res                         M                 N                     NT                    IV              \+                  --
  16               Res                         M                 N                     NA                    NA              \+                  --
  17               Res                         M                 D                     NT                    III             --                  --
  18               Res                         M                 NA                    NT                    II              --                  --
  19               Res                         M                 NA                    NT                    NA              \+                  --
  20               Res                         U                 N                     NA                    I               --                  --
  21               Res                         U                 N                     NT                    IV              --                  --
  22               Res                         U                 N                     T                     IV              --                  --
  23               Res                         U                 N                     NT                    NA              --                  --
  24               Res                         U                 D                     NA                    IV              --                  --
  25               Res                         U                 NA                    T                     II              --                  --
  26               Res                         U                 NA                    T                     NA              --                  --
  27               Sen                         M                 NA                    NT                    II              NA                  \+
  28               Sen                         NA                NA                    T                     NA              \+                  \+
  29               Sen                         NA                NA                    NT                    NA              NA                  \+
  30               Res                         M                 NA                    T                     I               \+                  \+

*Sen, Sensitive; Res, Resistant; D, Diabetic; H-High glucose; N, Non-diabetic; NA-Not available; M-Mutated; U-Unmutated; T-patients clinically treated; NT-patients not clinically treated; del13q-del13q14. All samples are negative for del11q deletion and naïve for ibrutinib treatment or other tyrosine kinase inhibitors*.

Cell culture and compound treatments
------------------------------------

To date, most of the studies made in CLL were performed with either none or supra-physiological glucose concentrations. In this study, we maintain CLL lymphocytes in physiological (5.5 mM) glucose concentration to describe CLL metabolism. Primary CLL cells were thawed and cultured overnight in AIM-V (GIBCO, 12055-091), 10% FBS at 37°C. Cells were seeded and treated in 5.5 mM glucose RPMI, prepared with a 1:1 mix of RPMI 1640 (Wisent, 350-000) and RPMI 1640 w/o glucose (GIBCO, 11879-020), 10% FBS, 25 mM HEPES, 100 U/mL penicillin/streptomycin, at 37°C and 5% CO~2~. Cells were treated for 24 or 48 h with the following compounds: Ibrutinib (Selleckchem, S2680), Oligomycin A (Sigma, 75351), 2-Deoxy-D-glucose (Sigma, D6134), Ritonavir (Selleckchem, S1185), Compound 968 (Calbiochem, 352010), DHEA (Sigma, D-063), AMPA (Sigma, 324817), Etomoxir (Sigma, E1905), N-Acetyl-L-cysteine (NAC) (Sigma, A7250), Fatty acid supplement (Sigma, F7050). The description of compounds and their targets is shown in Table [2](#T2){ref-type="table"}.

###### 

Compounds used to modulate CLL lymphocyte metabolism.

  **Name**                             **Abbreviation**   **Concentration**   **Target**                 **Process Affected**
  ------------------------------------ ------------------ ------------------- -------------------------- ----------------------------------------
  2-Deoxy-D-glucose (glucose analog)   2DG                2 mM                HK                         Glycolysis
  Dehydroepiandrosterone               DHEA               10 μM               G6PDH                      Pentose phosphate pathway
  (Aminomethyl)phosphonic acid         AMPA               10 mM               SHMT1/2                    One carbon metabolism
  Compound 968                         968                10 μM               Glutaminase (GLS)          Glutamine to Glutamate conversion
  Oligomycin A                         Oligo              2 μM                ATP synthase (Complex V)   Mitochondrial respiration
  Ritonavir                            Rito               10 μM               GLUT4                      Glucose uptake
  Etomoxir                             Eto                50--100 μM          CPT-1                      Fatty acid oxidation
  Ibrutinib                            Ibru               10 μM               BTK                        BCR signaling
  N-Acetyl-L-cysteine                  NAC                4 mM                                           Glutathione synthesis and xCT function
  Fatty acid supplement                FA                                                                Fatty Acid metabolism

Viability/mitochondrial reductive capacity assays
-------------------------------------------------

Metabolic Activity/Annexin V/Dead Cell Apoptosis Kit with C12 Resazurin, APC annexin V, and SYTOX® Green for Flow Cytometry (Invitrogen, V35114) was used following manufacturer instructions. Briefly, cells were collected 48 h after treatment, spun down at 1300 rpm at 4°C for 5 min. Then, cells were washed in 1X Annexin binding buffer \[Invitrogen, V13246 (5X)\], spun down at 1300 rpm at 4°C for 5 min, re-suspended in 250 μL of 1X Annexin binding buffer and stained with Sytox green, Resazurin, and APC-Annexin V. Data was collected by flow cytometry (BD FACSAria Fusion cell sorter) at 561-582/15 nm (C12-Resazurin), 488-530/30 nm (Sytox green), 640-670/30 nm (APC-Annexin V). Data analysis was done with FlowJo V.10 software (Systat Software Inc.).

Glucose, glutamine, glutamate, and ammonia quantification
---------------------------------------------------------

After 24 h treatment, cell media was collected for metabolite quantification in a NOVA Bioprofile Analyzer 400 at GCRC Metabolomics Core (McGill University). Glucose, glutamine, glutamate, and ammonia uptake (or secretion) were estimated by subtracting their concentration in conditioned media from their concentrations in fresh media and normalized to viable cell number (μM/10^∧^6 cells). Within the concentration of the metabolites above, the pH of conditioned media was documented for each sample. The pH was not affected by any treatment in any of the tested samples.

ROS levels determination
------------------------

After 24 h treatment, CellROX® Green Flow Cytometry Assay Kit (Invitrogen, C10492) was used as directed by the manufacturer. Data was collected by flow cytometry (BD FACSAria Fusion cell sorter) at 488--530/30 nm (CellRox), and 640--670/30 nm (Sytox red). Data analysis was done with FlowJo V.10 software (Systat Software Inc.).

Glutathione concentration determination
---------------------------------------

Oxidized and Reduced glutathione was determined with GSH/GSSG-Glo Assay (Promega, V6611). Briefly, 1.5 × 10^6^ viable cells were treated for 24 h with selected compounds. After treatment, cells were collected, re-suspended in 125 μL of 1X HBSS (Wisent, 311-512-CL), and 40 μL of each sample was treated to determine oxidized and reduced glutathione according to manufacturer instructions. Measurements were obtained after 1 h, using a FluoStar Optima Reader. A glutathione standard curve was done to calculate glutathione concentration in the samples.

NAD(P)H/NAD(P) determination
----------------------------

Oxidized and Reduced NAD(P) ratio was determined with NAD(P)/NAD(P)H-Glo Assay (Promega, G9081 \[NADPH/NADP\] G9071\[NADH/NAD\]). Briefly, 1.5 × 10^6^ viable cells were treated for 24 h with selected compounds. After treatment, cells were collected, re-suspended in 40 μL of 1X PBS, and treated to determine NAD(P) and NAD(P)H individually according to manufacturer instructions. Measurements were obtained after 1 h, using a FluoStar Optima Reader. The luminescence signal is proportional to the NAD(P) and NAD(P)H amount in the sample.

Immunoblotting analysis
-----------------------

Cell pellets were collected 24 h after treatment, protein samples were fractionated on 4--12% Criterion™ XT Bis-Tris gels (Bio-Rad, 3450124) in 1X-XT MOPS buffer (BioRad, 161-0788), and transferred to 0.22 μm nitrocellulose membranes (Bio-Rad, 1620112). Antibodies used in this study were directed against: GLUT1 (Fisher, PA5-16793), GLUT4 \[IF8\] (Santa Cruz, sc-53566), GS (BD Biosciences, 610517), GLS1 \[EP7212\] (Abcam, ab156876)---to assess for GAC and KGA isoforms, β-Actin (Santa Cruz, sc-1616). Western Blot band quantification was performed using ImageJ 1.49v software (NIH, USA).

Data analysis
-------------

*T*-test and paired *t*-test analysis were performed using Sigma Plot version 13.0. Differences were considered significant if the *p* value was \< 0.05.

Results and discussion {#s3}
======================

Ibrutinib sensitive and resistant CLL lymphocytes display differential basal metabolism
---------------------------------------------------------------------------------------

To study the metabolic traits associated with ibrutinib resistance, we used 30 samples from our primary CLL lymphocyte bank (Table [1](#T1){ref-type="table"}). All CLL samples were del11q negative, naïve to ibrutinib treatment, and 4 were del17p positive. Forty-eight hours of *in vitro* treatment with 10 μM ibrutinib resulted in a heterogeneous decrease in the survival fraction among the samples tested. We established ibrutinib sensitive and resistant sample subsets using the median of the sample population (0.68) as a cut-off (Figure [1A](#F1){ref-type="fig"}). An initial assessment of the effects of metabolic inhibition was done by treating del17p negative CLL lymphocytes with a series of inhibitors (Table [2](#T2){ref-type="table"}) for 48 h. Ibrutinib sensitive cells were slightly sensitive to both pentose phosphate pathway and one carbon cycle inhibition compared to ibrutinib resistant cells, suggesting that the former subset is more dependent on glucose metabolism for survival (Figure [1B](#F1){ref-type="fig"}). In contrast, although not statistically significant, cell viability in ibrutinib resistant lymphocytes tended to be more affected by the inhibition of fatty acid oxidation pathway---using etomoxir (Figure [1C](#F1){ref-type="fig"}).

![CLL lymphocytes display metabolic differences associated with ibrutinib sensitivity. **(A--C)** Survival fraction (relative to non-treated control \[NT\]) of CLL lymphocytes treated with metabolic inhibitors for 48 h, **(A)** (*n* = 26), **(B)** (*n* = 15--26), **(C)** (*n* = 11), (mean ± SEM). Basal metabolite uptake differences between ibrutinib sensitive and resistant CLL lymphocytes, **(D)** Glucose (*n* = 20), **(E)** Ammonia (*n* = 22), **(F)** Glutamine (*n* = 16), **(G)** Glutamate (*n* = 23). Negative values indicate metabolite excretion to the media. **(H)** Basal raw (Resazurin) signal of mitochondrial reductive capacity of ibrutinib sensitive and resistant CLL lymphocytes (*n* = 25). **(I)** Basal raw ROS (CellRox) signal of ibrutinib sensitive and resistant CLL lymphocytes (*n* = 25). Basal protein expression of ibrutinib sensitive and resistant CLL lymphocytes (relative to actin signal) **(J)** GLUT1 (*n* = 22) and **(K)** GLUT4 (*n* = 10), \**p* \< 0.05.](fonc-08-00411-g0001){#F1}

Ibrutinib sensitive and resistant CLL lymphocytes had comparable levels of basal glucose uptake and extracellular accumulation of ammonia (Figures [1D,E](#F1){ref-type="fig"}). However, ibrutinib resistant cells had a higher basal glutamine uptake (Figure [1F](#F1){ref-type="fig"}), accompanied by increased basal glutamate secretion when compared to ibrutinib sensitive cells (Figure [1G](#F1){ref-type="fig"}). The latter suggests heightened intracellular amino acid catabolism in ibrutinib sensitive cells, using transamination to obtain glutamate, followed by ammonia and α-ketoglutarate production by glutamate dehydrogenase (GDH). The expression of enzymes involved in glutamine metabolism---such as glutamate dehydrogenase, glutaminase (GLS) or glutamine synthetase (GS)---was comparable in CLL lymphocytes when analyzed vis a vis ibrutinib sensitivity (*unpublished results*). As well, mitochondrial metabolic activity and ROS generation were similar in both subsets, suggesting distinct compensation mechanisms to maintain mitochondrial homeostasis (Figures [1H,I](#F1){ref-type="fig"}). Additionally, basal glucose transporter (GLUT) 1 expression is higher in ibrutinib sensitive cells (Figure [1J](#F1){ref-type="fig"}), which could contribute to an increased dependence on glucose metabolism compared to their resistant counterparts. In line with this is the increased sensitivity of ibrutinib sensitive cells to pentose phosphate and one carbon cycle pathways. In contrast, GLUT4 expression was similar in both subsets, which is in line with a comparable cytotoxic effect of ritonavir (GLUT4 inhibitor) on CLL lymphocytes, regardless of ibrutinib sensitivity (Figure [1K](#F1){ref-type="fig"}). A differential expression, subcellular localization, or activity of glucose transporters might account for the equivalent levels of basal glucose uptake observed in ibrutinib sensitive and resistant subsets.

Ibrutinib sensitive and resistant CLL lymphocytes metabolic response to BTK inhibition
--------------------------------------------------------------------------------------

Recently, we reported that ibrutinib increases glucose as well as glutamine uptake; and that the supplementation with a cysteine analog (NAC) could rescue ibrutinib-induced cytotoxicity and ibrutinib-induced ROS levels ([@B35]). To further characterize the response of primary CLL lymphocytes to ibrutinib treatment we evaluated the redox status of glutathione (GSH), NAD, and NADP. The decrease in total glutathione levels upon ibrutinib treatment was comparable in both subsets (Figure [2A](#F2){ref-type="fig"}), as well as the decrease in reduced glutathione levels (Figure [2B](#F2){ref-type="fig"}), suggesting that the rise in ROS levels upon ibrutinib treatment might result from reduced glutathione synthesis rather than diminished NADPH availability for glutathione regeneration. In fact, ibrutinib did not affect the NADPH/NADP ratio in sensitive samples and tended to increase it in resistant samples (Figure [2C](#F2){ref-type="fig"}). In contrast, NADH/NAD ratio was not affected by ibrutinib in resistant samples but tended to decrease in ibrutinib sensitive samples (Figure [2D](#F2){ref-type="fig"}). The latter suggests that ibrutinib reduces the bio-energetic capacity in sensitive cells, which might partially contribute to the observed cell death in this subset after 48 h treatment.

![Metabolic and Redox effects of ibrutinib on CLL lymphocytes. **(A)** Quantification of total glutathione after 24 h treatment with ibrutinib (*n* = 15), (mean ± SEM). **(B)** Reduced/Oxidized glutathione ratio after 24 h treatment with ibrutinib (*n* = 14). **(C)** NADPH/NADP ratio after 24 h of ibrutinib treatment (*n* = 8) (mean ± SEM). **(D)** NADH/NAD ratio after 24 h of ibrutinib treatment (*n* = 11) (mean ± SEM). Metabolite uptake after 24 h of ibrutinib treatment. **(E)** Glutamine (*n* = 21) and **(F)** Glutamate (*n* = 20) (mean ± SEM), \**p* \< 0.05.](fonc-08-00411-g0002){#F2}

Ibrutinib sensitive cells increased their glutamine uptake in response to ibrutinib (Figure [2E](#F2){ref-type="fig"}). This effect was accompanied by heightened glutamate secretion, possibly due to increased glutamine deamination (Figure [2F](#F2){ref-type="fig"}). In contrast, glutamine uptake was not affected in response to ibrutinib in the resistant subset (Figure [2E](#F2){ref-type="fig"}), but extracellular glutamate accumulation was reduced in 4 out of 6 analyzed samples (Figure [2F](#F2){ref-type="fig"}). The latter suggests that ibrutinib favors glutamate depletion in resistant cells, perhaps by increasing glutamate dehydrogenase activity, promoting NADPH production (Figure [2C](#F2){ref-type="fig"}), and redirecting α-ketoglutarate (α-KG) to feed the TCA cycle. Since NADPH is not likely consumed to regenerate glutathione levels in resistant samples after ibrutinib treatment, its use in different pathways could be proposed.

Role of fatty acid oxidation on CLL lymphocyte ibrutinib resistance
-------------------------------------------------------------------

The contribution of fatty acid metabolism to CLL metabolic plasticity has been previously explored. Fatty acid synthesis is favored via citrate production by isocitrate dehydrogenase, in addition to the over-expression of enzymes associated with enhanced fatty acid oxidation ([@B26], [@B29]). Recently, ibrutinib-induced inhibition on free fatty acid synthesis has been reported ([@B40]), supporting the idea that ibrutinib plays a role in CLL cell metabolism.

Given that a compensatory activation of fatty acid oxidation may also contribute to sustain TCA cycle and to increase NADPH intracellular pools, we propose that resistant cells could increase fatty acid oxidation flux as an alternative to elevated glutamine uptake in the cell after ibrutinib treatment. It is unlikely that ibrutinib effects are attenuated by fatty acid uptake, since Fatty acid supplementation to cells treated with ibrutinib does not rescue cell viability in any subset (Figure [3A](#F3){ref-type="fig"}). Metabolic rewiring involving glucose-derived carbons could also be considered. For instance, the increase in acetyl-CoA availability could be promoted via Pyruvate dehydrogenase, and/or by redirecting glyceraldehyde-3-phosphate carbons for triglyceride production---via Triosephosphate isomerase (TPI), overexpressed in CLL ([@B27]).

![Inhibition of FAO decreases ibrutinib-induced cytotoxicity in CLL primary lymphocytes. **(A)** Survival fraction (relative to non-treated control) after 48 h treatment with ibrutinib alone or in combination with Fatty acids (FA), (*n* = 10). **(B)** Survival fraction (relative to non-treated control) after 48 h treatment with etomoxir alone or in combination with ibrutinib, (*n* = 12). **(C)** Total glutathione levels after 24 h treatment with etomoxir alone or in combination with ibrutinib (*n* = 11). Protein expression levels (relative to actin) after 24 h treatment with etomoxir alone or in combination with ibrutinib **(D)** GS (*n* = 11), **(E)** GAC (*n* = 10), **(I)** GLUT1 (*n*=10). **(F)** NADPH/NADP ratio (*n* = 8), and **(G)** NADH/NAD ratio (*n* = 11) after 24 h treatment with etomoxir alone or in combination with ibrutinib. **(H)** Relative ROS levels after 48 h treatment with etomoxir alone or in combination with ibrutinib (*n* = 12), (mean ± SEM). **(J)** Glucose uptake after 24 h treatment with ibrutinib and etomoxir (*n* = 8). \**p* \< 0.05, \*\**p* \< 0.001.](fonc-08-00411-g0003){#F3}

To assess the association of ibrutinib resistance with fatty acid metabolism rewiring, we evaluated the combination of ibrutinib and etomoxir. Etomoxir inhibits carnitine palmitoyltransferase I (CPT-1), hampering mitochondrial β-oxidation of fatty acids. We utilize etomoxir at concentrations commonly used in preclinical studies involving primary leukemic cells ([@B41]--[@B45]). We observed that the use of non-cytotoxic concentrations of etomoxir in the presence of 10 μM ibrutinib did not modify ibrutinib-induced cytotoxicity in ibrutinib sensitive subset (Figure [3B](#F3){ref-type="fig"}). Of note, non-cytotoxic concentrations of etomoxir decrease total GSH by 30% in sensitive cells (Figure [3C](#F3){ref-type="fig"}), perhaps reflecting the partial redirection of available glutamate to α-ketoglutarate production for TCA cycle homeostasis maintenance (at the expense of cystine import). Remarkably, etomoxir re-sensitized resistant cells to ibrutinib-induced cytotoxicity (Figure [3B](#F3){ref-type="fig"}). We found that the protein expression of enzymes related to glutamine metabolism is affected when ibrutinib resistant cells were treated simultaneously with ibrutinib and etomoxir. GS expression is decreased by 30% (Figure [3D](#F3){ref-type="fig"}), while glutaminase isoform GAC slightly decreased (Figure [3E](#F3){ref-type="fig"}), showing a preference to maintain intracellular glutamate pools over glutamine production. In these conditions, the reduced/oxidized NADP and NAD metabolite ratios remained at basal levels, regardless of ibrutinib sensitivity status (Figures [3F,G](#F3){ref-type="fig"}). However, heightened ROS levels were observed when treating CLL lymphocytes with ibrutinib plus etomoxir, similar to their ibrutinib-only treated counterparts (Figure [3H](#F3){ref-type="fig"}), a possible consequence of decreased total glutathione (Figure [3C](#F3){ref-type="fig"}).

The preservation of NADH/NAD ratio basal level could be a consequence of the utilization of glutamate by ibrutinib resistant cells to feed the TCA cycle, favoring the flux toward the oxidative reactions and providing reducing equivalents for mitochondrial respiration. In addition, these cells could promote PEPCK activity to use oxaloacetate for supplying reagents to one carbon cycle, compensating for decreased FAO-derived NADPH.

Interestingly, upon ibrutinib plus etomoxir treatment, sensitive cells displayed a higher expression of GLUT1 when compared to resistant CLL cells (Figure [3I](#F3){ref-type="fig"}). This is reflected in a tendency of ibrutinib sensitive cells to uptake more glucose than resistant cells upon ibrutinib plus etomoxir treatment (Figure [3J](#F3){ref-type="fig"}). The increased influx of glucose-derived carbons to one carbon cycle and the mitochondria might compensate for the lack of fatty acid-derived NADPH and mitochondrial-dependent NADH pools, respectively (Figures [3F,G](#F3){ref-type="fig"})---revealing differential metabolic responses between subsets.

Upon simultaneous inhibition of BTK and FAO, the reductive capacity associated to NAD and NADP is maintained, accompanied by a decrease of reduced glutathione in both subsets. Ibrutinib-induced cytotoxicity is associated with increased ROS levels in CLL lymphocytes ([@B35]). However, ibrutinib sensitive and resistant cell subsets exhibit similar ROS levels upon ibrutinib treatment (with or without etomoxir), revealing differential control of oxidative stress and/or cell death mechanisms. The evaluation of the expression and/or activity of enzymes involved in oxidative stress response---such as superoxide dismutase, catalase, or glutathione peroxidase---remains to be explored. As well, the level of ROS damage measuring lipid peroxidation could be estimated.

TP53 metabolic rewiring favors a catabolic metabolism
-----------------------------------------------------

TP53 is a modulator of central carbon metabolism and redox homeostasis ([@B30]--[@B33]). Since mitochondrial respiration and biogenesis are exacerbated in CLL lymphocytes positive for a deletion spanning the TP53 locus (*del17p*) it is likely that TP53 plays an important role in CLL metabolism as well ([@B34]). To begin to understand alterations in central carbon metabolism specifically associated with *del17p* in CLL, four samples from our primary cell bank were challenged with metabolic inhibitors (Table [1](#T1){ref-type="table"}). Curtailing glycolysis (2DG), glucose uptake (ritonavir), glutaminolysis (Compound 968), or FAO (etomoxir) was cytotoxic to *del17p* samples to the same extent as to *del17p* negative samples (Figure [4A](#F4){ref-type="fig"}). Conversely, basal differential metabolic reprogramming was revealed by the evaluation of key indicators of the cell redox state. NADH/NAD ratio is preferentially enhanced while the opposite was observed for NADPH/NADP levels in this subset, with respect to *del17p* negative cells (Figures [4B,C](#F4){ref-type="fig"}). Decreased NADPH/NADP could be attributed to heightened glutathione regeneration. In line with this, we observed that enhanced GSH/GSSG ratio is associated with *del17p*, but not with total glutathione levels (Figures [4D,E](#F4){ref-type="fig"}). Such metabolic organization promoted by *del17p* favors the maintenance of elevated mitochondrial metabolism, previously reported in a model of TP53 deficient CLL cells ([@B34]). In agreement with this, differences in basal ROS production are not associated with *del17p* status (Figure [4F](#F4){ref-type="fig"}).

![Effect of FAO inhibition in ibrutinib treated CLL lymphocytes positive for del17p. **(A)** Survival fraction (relative to non-treated control \[NT\]) after 48 h treatment with the indicated metabolic inhibitors (*n* = 20--30) (mean ± SEM). **(B)** Basal NADH/NAD ratio (*n* = 11), and **(C)** Basal NADPH/NADP ratio (*n* = 14) of CLL lymphocytes negative and positive to del17p. **(D)** Reduced/Oxidized glutathione ratio (*n* = 18), and **(E)** Basal total glutathione levels (*n* = 19) of CLL lymphocytes negative and positive to del17p. **(F)** Basal raw ROS (CellRox) signal on CLL lymphocytes negative and positive to del17p (*n* = 29). **(G)** Survival fraction (relative to non-treated control) after 48 h treatment with combinations of ibrutinib and etomoxir (*n* = 4). wt -del17p negative CLL lymphocytes.](fonc-08-00411-g0004){#F4}

Ibrutinib is considered a therapeutic option to treat CLL cases positive for del17p. When we analyzed the samples from our primary lymphocyte databank, three out of the four del17p positive samples were sensitive to ibrutinib (Figure [4G](#F4){ref-type="fig"}). Although increased number of samples should be considered, we observed that the inhibition of FAO re-sensitized our del17p CLL ibrutinib resistant sample to ibrutinib (Figure [3B](#F3){ref-type="fig"}), as it was observed for del17p negative cells. Our ongoing work is aimed at investigating the rewiring of glutamate, glucose and fatty acid metabolism in del17p positive cells upon ibrutinib treatment.

Conclusions and model {#s4}
=====================

Based on the obtained results, we propose that ibrutinib downregulates cell metabolism at the TCA cycle level, causing a decrease in glutamate availability by increasing its catabolism to feed the TCA cycle. In these conditions, ibrutinib resistant CLL lymphocytes carry out a compensation mechanism involving increased fatty acid oxidation flux. As well, glutamate export is inhibited, likely to sustain intracellular glutamate pools (Figure [5](#F5){ref-type="fig"}). The re-sensitization of the resistant subset upon simultaneous treatment with etomoxir and ibrutinib, reveals that fatty acid metabolism could be explored as a therapeutic target to overcome ibrutinib resistance.

![Model for metabolic rewiring associated to ibrutinib resistance in CLL lymphocytes. Upon ibrutinib treatment, ibrutinib resistant cells initiate a compensation mechanism increasing fatty acid oxidation metabolism as well as α-KG production from glutamate, to maintain mitochondrial homeostasis. In line with this, we propose that α-KG follows preferentially an oxidation process in the TCA. Transporters are colored in purple, enzymes in green, and inhibitors in red. Enzymes overexpressed in CLL lymphocytes are in bold green characters. Blue arrows indicate reactions increased in basal ibrutinib resistant cells compared to the sensitive subset. Purple arrows represent the processes that are increased in resistant cells upon ibrutinib treatment. Dashed red arrows represent the processes inhibited upon ibrutinib treatment. Brown arrows indicate the proposed alternative metabolic rewiring to increase fatty acid and Acetyl-CoA availability.](fonc-08-00411-g0005){#F5}
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